Abstract
Abstract PO-002: Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have